#Open journalism No news is bad news

Your contributions will help us continue to deliver the stories that are important to you

Support The Journal
Dublin: 13°C Saturday 19 September 2020
Advertisement

50 jobs created at Dublin pharmaceutical plant

Alexion Pharmaceuticals has already begun recruiting for the new jobs which are due to be in place by the end of the year.

File photo
File photo

A PHARMACEUTICAL COMPANY is to create approximately 50 new jobs in Dublin with the opening of a new office and laboratory facility.

Alexion Pharmaceuticals has already begun recruiting for the new jobs which are planned to be in place by the end of the year. The jobs will be in quality control, logistics functions and supply chain positions.

Alexion makes a drug called Soliris, which treats debilitating and life-threatening blood disorders. The company said its expanding Irish workforce will also manage the supply of other Alexion medicines in the coming years.

A senior executive at Alexion praised Ireland’s government and universities for the standard of education and training in the pharmaceutical area.

“For these reasons, we we continue to expand our global supply chain and quality team, we are very pleased to come to Ireland for its highly skilled and educated workforce,” said Stephen Squinto of Alexion.

“We look forward to the role that our new colleagues in Ireland will play in helping us to provide life-transforming medicines like Soliris to more patients in more countries worldwide.”

#Open journalism No news is bad news Support The Journal

Your contributions will help us continue to deliver the stories that are important to you

Support us now

Minister for Jobs Richard Bruton said that increasing the number of jobs in the pharmaceutical industry is a key part of the government’s Action Plan for Jobs and said the new positions were “another significant jobs boost for the sector”.

Read: Company sets up safety deposit vault as burglaries rise and people fear banks >

Read: Bruton welcomes Action Plan for Jobs progress but people are still struggling >

About the author:

Christine Bohan

Read next:

COMMENTS (8)